IGC (IGC) Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

India Globalization Capital, Inc. (“IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. As previously disclosed, IGC submitted IGC-AD1 to the U.S. Food and Drug Administration (“FDA”) under Section 505(i) of the Federal Food, Drug, and Cosmetic Act. IGC received approval to proceed with the trial from the FDA on July 30, 2020.

As previously announced, for Cohort 1, we administered one dose of the investigational new drug IGC-AD1 per day to trial participants. We increased the dosage to two doses of IGC-AD1 per day in Cohort 2, which was conducted from early February 2021 through mid-May 2021. The Data and Safety Monitoring Committee (“DSMC”) for IGC’s clinical trial, having reviewed the data obtained through Cohort 1 and Cohort 2, recommended progressing to Cohort 3, which consists of administering three doses per day. Participants are monitored daily for safety and certain behavioral changes using, among others, the Neuropsychiatric Inventory (NPI) scale and the Columbia-Suicide Severity Rating Scale (C-SSRS). The Phase 1 clinical trial on Alzheimer’s patients is currently anticipated to conclude during the July through September 2021 timeframe.

To IGC’s knowledge, this is the first human clinical trial using low doses of natural THC, a psychoactive member of the cannabinoid class of natural products produced by the Cannabis sativa plant, on Alzheimer’s patients. IGC is pleased to progress into Cohort 3 of its Phase 1 clinical trial on participants suffering from Alzheimer’s disease to continue testing the safety of IGC-AD1 at higher doses.

According to World Health Organization, Alzheimer’s disease is expected to impact approximately 50 million individuals worldwide by 2030. IGC-AD1 is intended to assist with symptom relief in individuals living with Alzheimer’s, who may suffer from agitation, restlessness, anxiety, irritability, apathy, disinhibition, delusions, hallucinations, and sleep or appetite changes, among other symptoms. As the disease progresses, individuals may suffer from loss of memory and dementia. This Phase 1 trial is currently testing IGC-AD1 for safety. Depending on the results of this first clinical trial phase and pending appropriate FDA approvals, IGC intends to pursue additional future trials for efficacy at a later date.

A Phase 1 clinical trial is the first step of a human clinical trial in a multi-step process designed to obtain regulatory approval for the marketing of a new pharmaceutical drug. This multi-step process for obtaining FDA approval is described in IGC’s annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on July 13, 2020.

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• Direct Digital Holdings (DRCT) Receives Nasdaq Non-compliance Notice
• Trump Media & Technology Group (DJT) Provides Additional Information to DJT Investors on Short Selling